This trial has completed recruitment on this platform, and is no longer accepting new referrals.
A research study conducted by Moderna is testing an investigational vaccine that may protect people who have received kidney or liver transplants from getting sick if they come into contact with SARS-COV-2, which causes COVID-19; also known as coronavirus.
Trial ID: NCT04860297
Researchers in the COVE Transplant Study are trying to find solutions to the COVID-19 pandemic that can help everyone – including those who have received a kidney or liver transplant.
The purpose of this study is to evaluate an investigational vaccine that may prevent illness after exposure to SARS-CoV-2, which causes COVID-19. There will be two participant groups in this study – a group of individuals who have had a solid organ transplant and are immunocompromised from the transplant, and a control group of individuals who are in good health. The control group is included as a comparison group to help understand how immune cells act after vaccination. Both groups will receive the COVID-19 vaccine.
Currently, we are enrolling for Part B of the Cove Transplant study. In Part B, currently enrolled participants and eligible participants (please see eligibility criteria below) who received the primary COVID-19 vaccination series (i.e. Pfizer, Moderna, Janssen/J&J) outside of the study will be offered a booster dose of the Moderna COVID-19 vaccine.
Participation in the COVE Transplant Study Part B may be up to 6 months and includes up to 5 visits to the study site and 6 phone calls.
Insurance is not needed to join this clinical trial, and compensation for your time will be available.
You will need to travel to one of the study clinics taking part in this clinical trial.
Sites are located in the cities/states identified with the red pin: